Novartis has gotten out in front of an FDA, and its competitors, by halting worldwide distribution of its generic Zantac. It took the step as regulators globally have instituted different approaches after discovering that a suspected cancer-causing impurity has been
read moreAdult smoking rates fell 2.2% from January to July 2019, the equivalent of 200 fewer smokers an hour. More: Fastest drop in smoking rates in over a decade Source: News
read moreFacebook and Instagram have announced that they will remove posts promoting ‘miracle’ cures and get-slim-quick products. More: Social media sites act on NHS crack down plea Source: News
read more‘Don’t Risk Your Research’ aims to raise awareness of the risks incompetence poses to patients, clinical research and organisations. More: IAOCR launches patient safety campaign Source: News
read moreThe designation was based on the Phase II NOBILITY study. More: FDA Breakthrough granted for Roche’s Gazyva Source: News
read moreType II diabetes costs the NHS £8.8 billion a year. More: Oral semaglutide trumps Jardiance, Januvia, Victoza in type II diabetes Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals